Education
About Us
Working with TipRanks
Follow Us
Avadel Pharmaceuticals (AVDL)
NASDAQ:AVDL
Total Valuation
Avadel Pharmaceuticals has a market cap or net worth of $657.08M. The enterprise value is $1.23B.
Market Cap$657.08M
Enterprise Value$1.23B
Share Statistics
Avadel Pharmaceuticals has 96.63M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding96.63M
Owened by Insiders11.36%
Owened by Instutions37.49%
Financial Efficiency
Avadel Pharmaceuticals’s return on equity (ROE) is -0.66 and return on invested capital (ROIC) is -36.37%.
Return on Equity (ROE)-66.13%
Return on Assets (ROA)-29.73%
Return on Invested Capital (ROIC)-36.37%
Return on Capital Employed (ROCE)-36.74%
Revenue Per Employee$899,558.511
Profits Per Employee-$259,744.681
Employee Count188
Asset Turnover1.03
Inventory Turnover0.75
Valuation Ratios
The current PE Ratio of Avadel Pharmaceuticals is -20.48. Avadel Pharmaceuticals’s PEG ratio is 0.27.
PE Ratio-20.48
PS Ratio5.91
PB Ratio13.54
Price to Fair Value13.54
Price to FCF-21.32
Price to Operating Cash Flow-21.32
PEG Ratio0.27
Income Statement
In the last 12 months, Avadel Pharmaceuticals had revenue of $169.12M and earned -$48.83M in profits. Earnings per share was -$0.52.
Revenue$169.12M
Gross Profit$153.84M
Operating Income-$42.40M
Pretax Income-$49.08M
Net Income-$48.83M
EBITDA-35.57M
Earnings Per Share (EPS)-0.52
Cash Flow
In the last 12 months, operating cash flow was -$46.72M and capital expenditures $0.00, giving a free cash flow of -$46.91M billion.
Operating Cash Flow-$46.72M
Free Cash Flow-$46.91M
Free Cash Flow per Share-$0.49
Dividends & Yields
Avadel Pharmaceuticals pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-4.69%
Earnings Yield-4.88%
Stock Price Statistics
Beta1.16
52-Week Price Change-60.95%
50-Day Moving Average8.09
200-Day Moving Average11.96
Relative Strength Index (RSI)35.31
Average Volume (3m)1.09M
Important Dates
Avadel Pharmaceuticals upcoming earnings date is May 12, 2025, Before Open.
Last Earnings DateMar 3, 2025
Next Earnings DateMay 12, 2025
Ex-Dividend Date―
Financial Position
Avadel Pharmaceuticals as a current ratio of 2.75, with Debt / Equity ratio of 0.02
Current Ratio2.75
Quick Ratio2.33
Debt to Market Cap<0.01
Net Debt to EBITDA1.40
Interest Coverage Ratio-3.91
Taxes
In the past 12 months, Avadel Pharmaceuticals has paid -$248.00K in taxes.
Income Tax-$248.00K
Effective Tax Rate0.50%
Enterprise Valuation
Avadel Pharmaceuticals EV to EBITDA ratio is -26.72, with an EV/FCF ratio of -20.26.
EV to Sales5.62
EV to EBITDA-26.72
EV to Free Cash Flow-20.26
EV to Operating Cash Flow-20.26
Balance Sheet
Avadel Pharmaceuticals has $73.78M in cash and marketable securities with $1.70M in debt, giving a net cash position of -$72.07M billion.
Cash & Marketable Securities$73.78M
Total Debt$1.70M
Net Cash-$72.07M
Net Cash Per Share-$0.75
Tangible Book Value Per Share$0.60
Margins
Gross margin is 90.97%, with operating margin of -25.07%, and net profit margin of -28.87%.
Gross Margin90.97%
Operating Margin-25.07%
Pretax Margin-29.02%
Net Profit Margin-28.87%
EBITDA Margin-21.03%
EBIT Margin-22.62%
Analyst Forecast
The average price target for Avadel Pharmaceuticals is $17.13, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$17.13
Price Target Upside156.05%
Analyst ConsensusStrong Buy
Analyst Count9
Revenue Growth Forecast504.79%
EPS Growth Forecast74.24%